Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E10030 (Pegpleranib) + Lucentis in Wet AMD
NCT01089517Phase 2Completed
- Sponsor
- IVERIC bio
- Start
- Mar 2010
- Primary completion
- Jun 2012
- Modality
- Polymer-based Nanoparticles, RNA Aptamers, DNA Aptamers
- Countries
- 1
01
Overview
A Phase 2 trial of pegpleranib in neovascular age-related macular degeneration (NVAMD), sponsored by IVERIC bio. Started Mar 2010; status: completed.
02
Drugs
pegpleranib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT01089517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01089517.